Hospital
Ella E. M. Brown Charitable Circle
Ella E. M. Brown Charitable Circle was paid $16.52M by Medicaid between Jan 2018 and Dec 2024, across 237 billing codes. Its largest line is 99285, emergency room visit (most serious) — 18% of everything it billed.
33Billing provider infoELLA E. M. BROWN CHARITABLE CIRCLE
MARSHALL, MI 49068
MARSHALL, MI 49068
33aNPI1861475360assigned 11/29/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.52M
24GClaims519,194
24DCodes billed237
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#52 of 86
Median peer was paid$21.55M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,614 | $2.10M | |
| 2019 | 65,172 | $2.01M | |
| 2020 | 57,501 | $1.80M | |
| 2021 | 81,103 | $2.69M | |
| 2022 | 86,470 | $2.69M | |
| 2023 | 91,588 | $2.83M | |
| 2024incomplete | 72,746 | $2.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 8,799 | 8,378 | $2.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 11,934 | 11,394 | $2.19M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 15,587 | 15,033 | $2.01M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.3% | 25,446 | 7,558 | $703K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 6,973 | 6,508 | $689K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 3,027 | 2,954 | $479K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 1,859 | 1,846 | $475K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.6% | 10,174 | 8,968 | $429K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.5% | 1,025 | 1,016 | $421K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.2% | 9,166 | 3,301 | $366K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.2% | 139 | 138 | $361K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 4,086 | 3,991 | $299K |
225 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 9,489 | $253K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 5,806 | $226K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.2% | 8,229 | $194K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 2,424 | $188K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 5,874 | $170K |
| G0378 | Hospital observation service, per hour | 1.0% | 2,739 | $166K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 362 | $165K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 10,761 | $162K |
| 97161 | <1% | 3,184 | $156K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,482 | $140K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,140 | $138K |
| 80061 | Lipid panel | <1% | 9,316 | $133K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,535 | $131K |
| 59025 | Fetal non-stress test | <1% | 1,382 | $129K |
| 43248 | <1% | 575 | $123K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 506 | $105K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,970 | $101K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,971 | $100K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,701 | $100K |
| 76801 | <1% | 1,660 | $98K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 953 | $98K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 981 | $96K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 837 | $95K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,060 | $93K |
| 80053 | Comprehensive metabolic panel | <1% | 30,084 | $91K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,711 | $83K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,397 | $77K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,252 | $76K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,333 | $62K |
| 80081 | <1% | 1,680 | $60K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,938 | $59K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 110 | $56K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,407 | $55K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,223 | $50K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,381 | $46K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,164 | $42K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 989 | $34K |
| 87631 | <1% | 4,917 | $34K | |
| 87653 | <1% | 1,629 | $30K | |
| 88142 | <1% | 2,717 | $30K | |
| 73630 | <1% | 1,730 | $30K | |
| 93976 | <1% | 546 | $29K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,346 | $27K |
| 97162 | <1% | 544 | $27K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,276 | $26K |
| 36415 | Collection of venous blood by venipuncture | <1% | 37,838 | $24K |
| 87480 | <1% | 2,091 | $23K | |
| 73130 | <1% | 1,568 | $22K | |
| 87510 | <1% | 2,044 | $22K | |
| 87660 | <1% | 1,954 | $21K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 155 | $20K |
| 82607 | <1% | 2,491 | $19K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,059 | $19K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 78 | $19K |
| 95811 | <1% | 36 | $19K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,395 | $18K |
| 74018 | <1% | 753 | $17K | |
| 86803 | <1% | 2,331 | $17K | |
| 73610 | <1% | 1,279 | $16K | |
| 84702 | <1% | 2,891 | $16K | |
| 97165 | <1% | 264 | $15K | |
| 84439 | <1% | 3,301 | $15K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 394 | $15K |
| 73030 | <1% | 801 | $14K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 289 | $13K |
| 76830 | Ultrasound, transvaginal | <1% | 211 | $13K |
| 72100 | <1% | 377 | $13K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,185 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,192 | $12K |
| 92523 | <1% | 98 | $12K | |
| 73560 | <1% | 821 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,628 | $11K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 39 | $10K |
| 85027 | <1% | 3,340 | $10K | |
| 87077 | <1% | 2,978 | $9K | |
| 82728 | <1% | 1,221 | $9K | |
| 87186 | <1% | 2,758 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,548 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,626 | $9K |
| 84481 | <1% | 937 | $8K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 513 | $8K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 436 | $8K |
| 76642 | <1% | 188 | $8K | |
| 93971 | <1% | 140 | $8K | |
| 87563 | <1% | 397 | $7K | |
| 81514 | <1% | 68 | $7K | |
| 86140 | <1% | 3,256 | $7K | |
| 73110 | <1% | 463 | $7K | |
| 86703 | <1% | 930 | $7K | |
| 86900 | <1% | 709 | $7K | |
| 86780 | <1% | 766 | $6K | |
| 83880 | <1% | 893 | $5K | |
| 82043 | <1% | 1,645 | $5K | |
| 83540 | <1% | 1,440 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,615 | $4K |
| 82950 | <1% | 1,638 | $4K | |
| 73562 | <1% | 225 | $4K | |
| 87481 | <1% | 93 | $4K | |
| 76536 | <1% | 69 | $4K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 18 | $4K |
| 72110 | <1% | 81 | $4K | |
| 86038 | <1% | 616 | $3K | |
| 20610 | <1% | 24 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 24 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,084 | $3K |
| 83550 | <1% | 648 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 53 | $3K |
| 83735 | <1% | 2,343 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 89 | $3K |
| 82570 | <1% | 1,003 | $3K | |
| 85652 | <1% | 2,272 | $3K | |
| 87070 | <1% | 908 | $3K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 82 | $2K |
| 81001 | <1% | 12,488 | $2K | |
| 93017 | <1% | 86 | $2K | |
| 81015 | <1% | 1,572 | $2K | |
| 80076 | <1% | 555 | $2K | |
| 82746 | <1% | 279 | $2K | |
| 85610 | <1% | 2,350 | $2K | |
| 84403 | <1% | 140 | $2K | |
| 70486 | <1% | 39 | $2K | |
| 70360 | <1% | 66 | $2K | |
| 83001 | <1% | 197 | $2K | |
| 94060 | <1% | 12 | $2K | |
| 83690 | <1% | 6,267 | $2K | |
| 93975 | <1% | 12 | $1K | |
| 87486 | <1% | 284 | $1K | |
| 87581 | <1% | 284 | $1K | |
| 10060 | <1% | 13 | $1K | |
| 84703 | <1% | 8,471 | $1K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 12 | $1K |
| 83020 | <1% | 199 | $1K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 17 | $1K |
| 86431 | <1% | 449 | $1K | |
| 83516 | <1% | 126 | $993.93 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 91 | $982.87 |
| 73502 | <1% | 52 | $974.63 | |
| 80074 | <1% | 41 | $899.86 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 39 | $874.72 |
| 84146 | <1% | 86 | $790.09 | |
| 84156 | <1% | 459 | $755.01 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,223 | $753.61 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 68 | $745.71 |
| 71271 | <1% | 12 | $703.78 | |
| 82670 | <1% | 41 | $676.39 | |
| 82565 | <1% | 254 | $673.13 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 106 | $636.29 |
| 82247 | <1% | 248 | $625.98 | |
| 85730 | <1% | 1,210 | $618.05 | |
| 96367 | <1% | 36 | $604.46 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,435 | $593.54 |
| 83655 | <1% | 76 | $573.28 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $530.97 |
| 84550 | <1% | 285 | $520.73 | |
| 86850 | <1% | 629 | $468.61 | |
| 94726 | <1% | 26 | $466.93 | |
| 72070 | <1% | 12 | $455.35 | |
| 86200 | <1% | 84 | $409.29 | |
| 82550 | <1% | 232 | $405.13 | |
| 84484 | <1% | 5,314 | $379.54 | |
| 85379 | <1% | 1,162 | $367.94 | |
| 83721 | <1% | 68 | $352.78 | |
| 86901 | <1% | 1,012 | $256.92 | |
| 73140 | <1% | 13 | $255.27 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 621 | $236.91 |
| 87205 | <1% | 165 | $230.76 | |
| 84460 | <1% | 67 | $201.41 | |
| 73090 | <1% | 13 | $189.44 | |
| 86160 | <1% | 18 | $162.24 | |
| 86696 | <1% | 14 | $158.21 | |
| 97014 | <1% | 20 | $146.60 | |
| 86162 | <1% | 13 | $137.40 | |
| 84450 | <1% | 44 | $132.24 | |
| 82785 | <1% | 12 | $127.40 | |
| 86225 | <1% | 25 | $126.62 | |
| 83002 | <1% | 12 | $115.88 | |
| 86141 | <1% | 15 | $115.87 | |
| 84402 | <1% | 12 | $110.49 | |
| 83605 | <1% | 1,760 | $107.94 | |
| 86695 | <1% | 14 | $107.77 | |
| 84100 | <1% | 57 | $107.70 | |
| 86706 | <1% | 15 | $101.25 | |
| 82784 | <1% | 12 | $87.18 | |
| 82951 | <1% | 12 | $84.26 | |
| 87340 | <1% | 12 | $78.49 | |
| 82962 | <1% | 2,929 | $78.19 | |
| 85018 | <1% | 86 | $73.19 | |
| 76820 | <1% | 19 | $64.84 | |
| 87040 | <1% | 786 | $61.59 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 14 | $52.40 |
| 96376 | <1% | 1,630 | $52.38 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 606 | $46.43 |
| 87807 | <1% | 269 | $44.14 | |
| 81003 | <1% | 951 | $37.92 | |
| 96127 | <1% | 12 | $37.90 | |
| 86592 | <1% | 14 | $34.84 | |
| 87210 | <1% | 407 | $19.91 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 181 | $11.89 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,844 | $9.36 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,301 | $8.83 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 947 | $4.60 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,879 | $2.42 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 5,314 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 163 | $0.00 |
| 90715 | 0% | 217 | $0.00 | |
| A6216 | Gauze, non-impregnated, non-sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 694 | $0.00 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 542 | $0.00 |
| A6254 | Specialty absorptive dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 40 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 188 | $0.00 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 291 | $0.00 |
| 94729 | 0% | 27 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 27 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 53 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 19 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 281 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 2,431 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 2,814 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 678 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 133 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 201 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 605 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 106 | $0.00 |
| J8501 | Aprepitant, oral, 5 mg | 0% | 66 | $0.00 |
| 12001 | 0% | 13 | $0.00 | |
| 73060 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKOPPENHAVER, COLLEEN (CHIEF FINANCIAL OFFICER)